TDO2 inhibitors
Grant
US12583858B2
Kind: B2
Mar 24, 2026
Assignee
Genentech, Inc.
Inventors
Xingyu Lin, Po-wai Yuen, Rohan Mendonca, Brendan Parr, Richard Pastor, Zhonghua Pei, Lewis Gazzard, Firoz Jaipuri, Sanjeev Kumar, Xiaokai Li, Roheeth Pavana, Hima Potturi, Venkata Velvadapu, Jesse Waldo, Zuhui Zhang, Guosheng Wu, Benjamin Douglas Sellers
Abstract
Presently provided are inhibitors of cellularly expressed TD02 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
CPC Classifications
C07D 487/04
C07D 519/00
A61K 38/16
A61K 45/06
A61K 2300/00
A61P 35/00
A61P 35/02
Filing Date
2020-10-12
Application No.
17068574
Claims
14